Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 479 results found since Jan 2013.
Fight Aging! Newsletter, May 4th 2020
The objective is to start treating chronic diseases from the root and not the symptoms of the disease. As we are starting to enroll patients in "senolytics-clinical trials," it will be imperative to assess if senolysis efficiently targets the primary cause of disease or if it works best in combination with other drugs. Additional basic science research is required to address the fundamental role of senescent cells, especially in the established contexts of disease.
Notes on Self-Experimentation with Sex Steroid Ablation for Regrowth of the Thymus
https://www.fightaging.org/archives/2020/04/notes-on-self-experim...
Source: Fight Aging! - May 3, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
The False Choice Between Science And Economics
This article originally appeared on The Bulwark here.
The post The False Choice Between Science And Economics appeared first on The Health Care Blog.
Source: The Health Care Blog - May 1, 2020 Category: Consumer Health News Authors: Christina Liu Tags: COVID-19 Health Policy David Shaywitz Source Type: blogs
Top 20 Research Studies of 2019 for Primary Care Physicians.
This article summarizes the clinical questions and bottom-line answers from the top 20 POEMs of 2019. Taking blood pressure medications at night results in a large mortality reduction over six years compared with morning dosing. Automated devices are the best way to measure blood pressure. Nonfasting lipid profiles are preferred over fasting lipid profiles, and nonfasting and fasting lipid profiles are equally effective at predicting risk. The benefit of statins for primary prevention in people 75 years and older is uncertain at best. Aspirin has no net benefit for primary prevention of cardiovascular disease and has no ef...
Source: Pain Physician - May 1, 2020 Category: Anesthesiology Authors: Ebell MH, Grad R Tags: Am Fam Physician Source Type: research
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Microneedle Array for Universal Vaccine Delivery Developed
Microneedle arrays (MNAs) are a promising way of delivering vaccines into the body. They are nearly pain-free and can penetrate a substantial portion of the skin, which is considered an excellent place to inject vaccines because of the skin’s s...
Source: Medgadget - April 22, 2020 Category: Medical Devices Authors: Medgadget Editors Tags: Medicine Public Health Source Type: blogs
U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s milestone mar...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
8-Puff Dry-Powder Inhaler Wins Red Dot Product Design Award
Hovione Technology’s 8Shot Dry Powder Inhaler (DPI) has earned the Red Dot 2020 Product Design Award in the Healthcare Daily Living AIDS category.
João Ventura Fernandes, PhD, director of technology development and licensing for Hovione Technology Ltd., told MD+DI that 8Shot “was developed to be the world’s first 8-dose, factory-filled dry powder inhaler device enabling effective and safe drug delivery to the lungs of a range of drugs expected to be developed and reach the market during the next years." It is targeted for "delivery of new pharmaceutical c...
Source: MDDI - April 21, 2020 Category: Medical Devices Authors: Daphne Allen Tags: Design Source Type: news
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide.
A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news
Is it safe to see the pediatrician for vaccines and medical visits?
We’re tackling a few urgent questions from parents in this time of coronavirus and COVID-19. Are you wondering if babies and children should continue to have vaccines on schedule? Thinking about how to manage regular medical appointments, and which situations require in-person visits to a pediatric practice? Read on.
Should parents take babies for initial vaccines right now? What about toddlers and older children who are due for vaccines?
The answer to this question is going to depend on many factors, including what your doctor’s office is offering. As with all health care decisions, it comes down to weighing risks and...
Source: Harvard Health Blog - March 31, 2020 Category: Consumer Health News Authors: Claire McCarthy, MD Tags: Adolescent health Children's Health Health care Parenting Vaccines Source Type: blogs
Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “While we contin...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society.
CONCLUSIONS: Certain conditions are prevalent in the same patient populations that are vaccinated with the HPV vaccine (peri-pubertal males and females). This association, however, is insufficient proof of causality.
PMID: 31928708 [PubMed - in process]
Source: Autonomic Neuroscience - December 31, 2019 Category: Neuroscience Authors: Barboi A, Gibbons CH, Axelrod F, Benarroch EE, Biaggioni I, Chapleau MW, Chelimsky G, Chelimsky T, Cheshire WP, Claydon VE, Freeman R, Goldstein DS, Joyner MJ, Kaufmann H, Low PA, Norcliffe-Kaufmann L, Robertson D, Shibao CA, Singer W, Snapper H, Vernino Tags: Auton Neurosci Source Type: research
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
CONCLUSIONS: The immunogenicity of two-dose and three-dose HPV vaccine schedules, measured using antibody responses in young females, is comparable. The quadrivalent vaccine probably reduces external genital lesions and anogenital warts in males compared with control. The nonavalent and quadrivalent vaccines offer similar protection against a combined outcome of cervical, vaginal, and vulval precancer lesions or cancer. In people living with HIV, both the bivalent and quadrivalent HPV vaccines result in high antibody responses. For all comparisons of alternative HPV vaccine schedules, the certainty of the body of evidence ...
Source: Cochrane Database of Systematic Reviews - November 21, 2019 Category: General Medicine Authors: Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros-Balta AX, Low N, Henschke N Tags: Cochrane Database Syst Rev Source Type: research
New Cochrane Review assesses different HPV vaccines and vaccine schedules in adolescent girls and boys
New evidence published in the Cochrane Library today provides further information on the benefits and harms of different human papillomavirus (HPV) vaccines and vaccine schedules in young women and men.HPV is the most common viral infection of the reproductive tract in both women and men globally (WHO 2017). Most people who have sexual contact will be exposed to HPV at some point in their life. In most people, their own immune system will clear the HPV infection.HPV infection can sometimes persist if the immune system does not clear the virus. Persistent infection with some ‘high-risk’ strains of HPV can lead to the de...
Source: Cochrane News and Events - November 20, 2019 Category: Information Technology Authors: Katie Abbotts Source Type: news
